Literature DB >> 6573138

Aspirin therapy in vernal conjunctivitis.

M B Abelson, S I Butrus, J H Weston.   

Abstract

Prostaglandin D2 is a secondary mast cell mediator that causes redness, chemosis, mucous discharge, and eosinophil chemotaxis in the eye. It may play an important role in allergic ocular disease. Although histamine is a key mediator of allergic inflammation, antihistamine therapy provides only symptomatic relief. We added aspirin therapy to the treatment regimen of three patients with vernal conjunctivitis. Aspirin acetylates the enzyme cyclooxygenase, thereby preventing the formation of prostaglandin D2. Within two weeks after initiation of aspirin therapy, we noted dramatic improvement in conjunctival and episcleral redness and resolution of keratitis and limbal infiltration. We recommend a trial of oral aspirin as adjunctive therapy for intractable cases of vernal conjunctivitis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6573138     DOI: 10.1016/0002-9394(83)90272-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  10 in total

Review 1.  Ocular allergy treatments.

Authors:  L Bielory
Journal:  Clin Rev Allergy Immunol       Date:  2001-04       Impact factor: 8.667

Review 2.  Ocular allergy in pediatric practice.

Authors:  Mark B Abelson; David Granet
Journal:  Curr Allergy Asthma Rep       Date:  2006-07       Impact factor: 4.806

Review 3.  [Ocular allergies].

Authors:  E M Messmer
Journal:  Ophthalmologe       Date:  2005-05       Impact factor: 1.059

Review 4.  Ocular allergies.

Authors:  L Fonacier; J Luchs; I Udell
Journal:  Curr Allergy Asthma Rep       Date:  2001-07       Impact factor: 4.806

5.  Preservative-free diclofenac sodium 0.1% for vernal keratoconjunctivitis.

Authors:  Gennaro D'Angelo; Alessandro Lambiase; Magdalena Cortes; Roberto Sgrulletta; Roberta Pasqualetti; Ambra Lamagna; Stefano Bonini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-02-15       Impact factor: 3.117

Review 6.  Therapeutic options in ocular allergic disease.

Authors:  M Hingorani; S Lightman
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 7.  Drug treatment of allergic conjunctivitis. A review of the evidence.

Authors:  G Ciprandi; S Buscaglia; P M Cerqueti; G W Canonica
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

8.  Levels of prostaglandin E2 and leukotriene B4 in tears of vernal conjunctivitis patients during a therapeutic trial with indomethacin.

Authors:  H Nathan; N Naveh; E Meyer
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

9.  Levocabastine eye drops in the treatment of vernal conjunctivitis.

Authors:  F Goes; S Blockhuys; M Janssens
Journal:  Doc Ophthalmol       Date:  1994       Impact factor: 2.379

10.  Management of vernal keratoconjunctivitis.

Authors:  Andrea Leonardi
Journal:  Ophthalmol Ther       Date:  2013-09-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.